GlobeNewswire by notified

Champalimaud Foundation partners with Philips to reduce its diagnostic imaging carbon footprint by 50% in five years

Share

March 15, 2023

Lisbon, Portugal and Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and leading Portuguese translational biomedical research and clinical care provider Champalimaud Foundation, today announced they have signed a strategic partnership aimed at halving the carbon footprint resulting from Champalimaud’s use of diagnostic and interventional imaging equipment by 2028.

The transformation of Champalimaud Foundation’s imaging technology infrastructure will be enabled by a set of practical, scalable measures and innovations, including equipment upgrades, lifetime extensions, process digitalization, circular financing solutions with takeback, and renewable electricity sourcing. It will help drive the quality and efficiency of care delivery, while also realizing more sustainable healthcare. As a result, many more patients are expected to be able to benefit from the hospital’s diagnostic healthcare services.

Global healthcare systems account for 4.4% of global CO₂ emissions [1] – more than aviation or the shipping industry [2]. The cooperation between Champalimaud Foundation and Philips is based on a shared commitment to help mitigate climate change – building on Philips’ acknowledged expertise as a health technology company that is driving systemic change towards more sustainable and equitable patient care through the application of EcoDesign (embedding sustainability into the innovation process), circular economy principles, renewable energy sourcing, and workflow improvement through digitalization.

After conducting a baseline assessment of Champalimaud Foundation’s current CO₂ emissions, Philips will work with the organization to update and renew its diagnostic imaging technology capabilities, keeping it up-to-date with Philips’ latest innovations in diagnostic imaging such as CT and MR systems, while also reducing resource demand, increasing the use of recycled materials, and extending equipment lifespans. As a result, Champalimaud Foundation’s patients and staff will be able to enjoy the outcome benefits of advanced diagnostic imaging coupled with improved patient and staff experiences and more sustainable healthcare delivery.

“The healthcare sector is a significant contributor to CO₂ emissions and therefore has an important role to play in mitigating climate change,” said Leonor Beleza, President of the Champalimaud Foundation. “This partnership will allow us to continue to ensure the best care for our patients while at the same time helping to reduce the healthcare sector’s environmental impact.”

“Alongside improving patient outcomes and increasing efficiency, healthcare providers are increasingly focusing on mitigating their impact on the climate and making more sustainable choices,” said Peter Vullinghs, Market Leader Western Europe for Philips. “We have a strong track record in embedding sustainability in our solutions, our operations, and across our supply chain. Leveraging that deep expertise, we are partnering with the Champalimaud Foundation to make a step-change in their environmental impact, while enabling them to pursue their goal of advancing the prevention, early diagnosis and treatment of cancer.”

Philips will support Champalimaud Foundation’s sustainability targets through a range of health technologies and innovations designed to reduce the foundation’s dependency on natural resources and energy consumption. This includes the installation of Philips Spectral CT 7500 which uses 62.5% less energy [3]. The installation of Philips’ MR helium-free operations’ system, Philips MR – Ingenia Ambition 1.5T that uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips’s systems. Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [4].


Philips will also take back the currently-installed Philips equipment and ensure responsible end-of-use management, to avoid waste going to landfill. In addition, Philip will help the Champalimaud Foundation implement hybrid operating room solutions, providing its specialists with a wide range of image-guided minimally-invasive interventional procedures with enhanced precision and patient safety, resulting in shorter hospitalization compared to traditional surgical interventions. 

[1] Health Care Without Harm (2019). Health care’s climate footprint: How the health sector contributes to the global climate crisis and opportunities for action (p.22). https://noharm-global.org/documents/health-care-climatefootprint-report Scope 1 direct emissions originate from the hospitals’ own operations: emissions from the building and transportation. Scope 2 indirect emissions are generated by the production and distribution of energy that is consumed by the hospital. Scope 3 are indirect CO2 emissions caused by the production and transportation of goods and services needed by hospitals such as medicines, food, equipment, clothing and waste treatment.
[2] https://www.bmj.com/content/366/bmj.l5560
[3] When compared to an equivalent CT model of one of the industry leaders
[4] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.


For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

Afonso Vaz Pinto
Champalimaud Foundation
E-mail: avazpinto@jlma.pt
Tel: +34 969 658 256

Raul Araújo
Champalimaud Foundation
Email: raraujo@jma.pt
Tel: +34 927 414 665

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Champalimaud Foundation:

The Champalimaud Foundation was created in 2004 by the last will and testament of the Portuguese entrepreneur António Champalimaud. It is one of the largest European foundations dedicated to scientific research in the field of Medicine. The Champalimaud Foundation essentially supports research in neurosciences, cancer and vision.
 The mission of the Champalimaud Clinical Center (CCC) is to actively develop advanced research and technological innovation programs, alongside the interdisciplinary delivery of clinical care in the prevention, early diagnosis and treatment of cancer. Its clinical activity is patient-centered, through the personalization of care and promotion of quality of life, providing excellence in care, based on multidisciplinary teams, and providing patients with the opportunity to participate in innovative diagnostic and treatment programs.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

McWhorter Foundation Preparing Legal Battle Against J.P. Morgan Over IPO Discrimination and LBO Biases28.3.2024 19:28:47 CET | Press release

PALM BEACH, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- McWhorter Foundation is poised to launch a groundbreaking legal battle against financial giant J.P. Morgan. With a focus on challenging discriminatory practices in leveraged buyouts (LBOs) and initial public offerings (IPOs), The McWhorter Foundation aims to break down barriers and advocate for equal access to capital markets. Exposing Inequities in IPOs: Recent analyses have highlighted disparities in IPO access, with minority-owned businesses facing systemic hurdles in accessing public markets. McWhorter's legal challenge will illuminate these inequities, compelling J.P. Morgan to address its role in perpetuating barriers to entry for underrepresented entrepreneurs. Leveraging Data for Change: Backed by comprehensive data and extensive research, McWhorter's legal team will present compelling evidence of discrimination in J.P. Morgan's IPO practices. By highlighting patterns of exclusion and unequal treatment, McWhorter Foundation s

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC28.3.2024 19:00:00 CET | Press release

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it held 0 (zero) shares of the then outstanding 5,753,951,723 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press rele

C.K. McWhorter: Running to a Solution Of Equality and Sustainability28.3.2024 18:48:29 CET | Press release

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking endeavor, C.K. McWhorter, renowned for his pioneering spirit in luxury and finance, is embarking on a transformative journey to reshape the narrative of desirability. By harnessing the allure of luxury, McWhorter aims to catalyze a paradigm shift towards equality and sustainability, ensuring that these principles become the most coveted and revered ideals worldwide. With a profound understanding of the power of influence, McWhorter recognizes that luxury sets the standard for aspiration and desire. Leveraging this influence, he seeks to redefine what it means to truly desire and value, shifting the focus from just material possessions to ethical principles that benefit humanity and the planet. "Luxury has long been synonymous with opulence and exclusivity, but it's time for us to redefine its meaning," says McWhorter. "True luxury is in equality and sustainability – in knowing that our desires are aligned with values that up

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond28.3.2024 18:30:00 CET | Press release

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond Guidance for 2023 achieved: EBIT plus 44.8% to EUR 45.6 million Revenue up 8.5 % to EUR 230.5 millionNet profit jumped to EUR 16.4 million, basic earnings per share amount to EUR 0.51 Loans to customers and debt investments increased by 20.8% to EUR 638.1 million, impaired loan coverage ratio decreased to 16.6%Dividend proposal of EUR 0.19 per shareStrong confidence for outlook: 2024: EBIT guidance of EUR 67.5 million Mid-term 2026: net profit growth to EUR 30 million Helsinki, 28 March 2024 – Multitude SE, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized businesses, and other FinTechs (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude”, “Company” or “Group”) announces that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the financial year ended 31 December 2023 have been

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS28.3.2024 18:30:00 CET | Press release

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 25 April 2024 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte

HiddenA line styled icon from Orion Icon Library.Eye